CHK1/FLT3双重抑制增强细胞毒性并克服FLT3-ITD急性髓系白血病的适应性及获得性耐药
研究观察到CHK1抑制剂可协同增强FLT3抑制剂对FLT3突变急性髓系白血病细胞的疗效,并克服适应性耐药。研究鉴定出具有良好口服药代动力学特征的双重FLT3/CHK1抑制剂30,其可抑制FLT3和CHK1、下调c-Myc通路并激活p53通路,在体外对多种FLT3突变细胞更具选择性、克服适应性耐药,在体内有效抑制耐药性FLT3-ITD急性髓系白血病。
要点
- CHK1抑制剂可协同增强FLT3抑制剂对FLT3突变急性髓系白血病细胞的疗效并克服适应性耐药。
- 双重FLT3/CHK1抑制剂30在体外对多种FLT3突变细胞更具选择性并克服适应性耐药。
- 30在体内有效抑制耐药性FLT3-ITD急性髓系白血病,且无显著血液毒性或骨髓抑制。
核心结论
- 靶向FLT3和CHK1是克服急性髓系白血病中FLT3抑制剂治疗适应性及获得性耐药的新策略,30是有潜力的临床候选药物。
研究设计与样本
- 研究在FLT3突变急性髓系白血病细胞中观察CHK1抑制剂与FLT3抑制剂的协同作用,并鉴定双重FLT3/CHK1抑制剂30。
- 研究进行了机制研究、体外功能研究及体内耐药FLT3-ITD急性髓系白血病模型研究,并在比格犬中评估药代动力学。
主要发现
- CHK1抑制剂可协同改善FLT3抑制剂在FLT3突变急性髓系白血病细胞中的治疗效果,联合方案克服适应性耐药。
- 30抑制FLT3和CHK1,下调c-Myc通路并进一步激活p53通路。
- 30在体外对多种FLT3突变细胞更具选择性并克服适应性耐药,在体内有效抑制耐药性FLT3-ITD急性髓系白血病。
- 30在比格犬中表现出良好口服药代动力学特征,T1/2超过12小时,且无显著血液毒性或骨髓抑制。
临床怎么用
- 原文结论支持靶向FLT3和CHK1作为克服FLT3抑制剂治疗适应性及获得性耐药的新策略,并提示30为潜在临床候选药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FLT3 inhibitors (FLT3i) are widely used for the treatment of acute myeloid leukemia (AML), but adaptive and acquired resistance remains a primary challenge. Inhibitors simultaneously blocking adaptive and acquired resistance are highly demanded. Here, we observed the potential of CHK1 inhibitors to synergistically improve the therapeutic effect of FLT3i in FLT3-mutated AML cells. Notably, the combination overcame adaptive resistance. The simultaneous targeting of FLT3 and CHK1 kinases may overcome acquired and adaptive resistance. A dual FLT3/CHK1 inhibitor 30 with a good oral PK profile was identified. Mechanistic studies indicated that 30 inhibited FLT3 and CHK1, downregulated the c-Myc pathway and further activated the p53 pathway. Functional studies showed that 30 was more selective against cells with various FLT3 mutants, overcame adaptive resistance in vitro, and effectively inhibited resistant FLT3-ITD AML in vivo. Moreover, 30 showed favorable druggability without significant blood toxicity or myelosuppression and exhibited a good oral PK profile with a T1/2 over 12 h in beagles. These findings support the targeting of FLT3 and CHK1 as a novel strategy for overcoming adaptive and acquired resistance to FLT3i therapy in AML and suggest 30 as a potential clinical candidate.
引用
- Jiang K, Li X, Wang C, et al. Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia. Leukemia. 2022. PMID: 36526736. doi:10.1038/s41375-022-01795-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。